NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_80hr,"Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,22.78453803998,1.0066914494057244,27.666365005975898,1.44195210234481,7.54436328808604,22.7837130746583,percent_activity,2,22.6330898642581,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.71382744442186,1.71382744442186,1.32264310324049,20,nuclear receptor
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,0.852596716580562,2.3291925081839078,32.75742425391918,1.51530974546054,0.122016065451132,0.696721723612493,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.42303754072093,1.42303754072093,0.802860783609802,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,39.7859894101768,1.3742629628881224,23.924682480214862,1.37884618268689,9.65026114229828,33.1459542825541,percent_activity,2,28.9507834268948,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.76665800582897,1.76665800582897,0.511820744819086,20,cell cycle
APR_HepG2_CellCycleArrest_24h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.926361704739857,1.3146497131752466,102.15012029149727,2.00923888239189,0.070464527201123,0.771968087346375,log2_fold_induction,2.30102999566398,0.70464527201123,"[""Borderline active"",""Borderline active""]",2.25178806671376,1.75363797596472,1.54834015007256,20,cell cycle
APR_HepG2_p53Act_24h_up,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,2.143005206901295,2.205067574271427,93.31480940441317,1.969950573352365,0.09718546641861357,1.78583767245984,log2_fold_induction,2.30102999566398,0.9718546641861358,,1.9263044718018383,1.5374359444777541,1.4558381754269625,20,dna binding
APR_HepG2_p53Act_72h_up,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,2.33351804258511,1.9747163756369244,106.88165506032648,2.02890317022505,0.118169782322915,2.02196670135311,log2_fold_induction,2.30102999566398,1.18169782322915,,2.03263728880265,1.77815867371238,1.70851665986749,20,dna binding
APR_HepG2_P-H2AX_24h_up,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,1.09022820447021,1.327717306034436,91.04493872837881,1.95925580797353,0.0821129768750588,0.908523503750649,log2_fold_induction,2.30102999566398,0.821129768750588,"[""Borderline active"",""Borderline active""]",2.21564463962244,1.67627465135651,1.4542881979204,20,dna binding
APR_HepG2_P-H2AX_72h_up,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,1.58629881456935,1.446534656126708,104.48835016913078,2.01906787188917,0.109661998615151,1.41695210142097,log2_fold_induction,2.30102999566398,1.09661998615151,,2.12623031423618,1.84086435684825,1.72702026946551,20,dna binding
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1", , , ,,,Active,0.7547597191595851,1.2715977110056622,58.04504903998922,1.7637651824499603,0.11871045577184501,0.6289664326551687,log2_fold_induction,2.30102999566398,0.593552278859225,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",2.3983313490495455,1.708883543630738,0.6940638288982739,20,nuclear receptor
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,3.4384610760023127,3.111298358614486,44.66502880833403,1.649967618438928,0.22103062321117403,2.8653842300028316,log2_fold_induction,2.30102999566398,1.10515311605587,,1.2769420171265247,0.9353539981357192,0.5531957387704223,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.374398241362123,2.7199081323007017,40.95712378949143,1.6123294507458166,0.10106210757931403,1.1453318678461453,log2_fold_induction,2.30102999566398,0.5053105378965701,,1.3676319596325328,1.0427676526309955,0.6208409468392533,20,nuclear receptor
ATG_FXR_TRANS_up,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,1.0051392652100362,1.2133974495086643,163.77703971081039,2.2142530169248196,0.16567354177595192,0.8376160548173917,log2_fold_induction,2.30102999566398,0.8283677088797596,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.2981043664014225,2.2130541774533965,2.094972699632441,20,nuclear receptor
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,0.7683676011538516,1.1338037571661868,632.455531963062,2.801029995615492,0.13553802345377633,0.7115379813886937,log2_fold_induction,2.30102999566398,0.6776901172688816,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",5.712802300487411,2.9702620760956155,-0.3797783688656837,20,dna binding
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[72,36,58,34,163,34,36,58,72,163]",,Active,1.453678845550384,1.2668609275402598,57.25126432002004,1.7577850819489576,0.2294930428350727,1.2113990380077577,log2_fold_induction,1.84509804001426,1.1474652141753636,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.8295051764516528,1.7520491218876348,1.6384952570284392,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,1.749534612056579,1.358283062141247,29.305219392057214,1.466944977053695,0.2576097222766731,1.6047196439947362,log2_fold_induction,2.30102999566398,1.2880486113833656,"[""Hit-call potentially confounded by overfitting""]",1.8166810268163083,1.3871708755456136,0.7182848636205399,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1, , , ,,,Active,2.64239572619174,2.6599623928469667,19.81597829534883,1.2970155178906895,0.19867917932204862,2.8650754063565445,log2_fold_induction,1.84509804001426,0.9933958966102431,,1.2695032366933874,1.2300520125378993,1.1777352039111613,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2, , , ,"[148,148]",,Active,0.6466096672070893,1.2307077567772353,41.69702770899301,1.6201050982449878,0.10507931938290839,0.5936631161336592,log2_fold_induction,2.30102999566398,0.525396596914542,"[""Borderline active""]",2.059942365410291,1.605136104406957,0.9611531327050692,20,dna binding
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.38543339968136703,2.9605306843859998,39.99999999999999,1.6020599913279623,0.04339688170481999,0.251154325,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,-1.243634126528986,20,cytokine
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1, , , ,,,Active,0.2208353999926851,1.6527256294885222,39.99999999999999,1.6020599913279623,0.04453963724175,0.18123333000000003,log10_fold_induction,1.60205999132796,0.13361891172525,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,-0.5073553770758846,20,protease
BSK_CASM3C_TissueFactor_down,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.20306221172480768,1.776014967504195,39.99999999999999,1.6020599913279623,0.038111955781199996,0.150739165,log10_fold_induction,1.60205999132796,0.11433586734359999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.6767806210824736,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.17695737260619454,1.3059239529799656,40.000000000000014,1.6020599913279625,0.0451678604517,0.14195877,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,-1.1047547176001142,20,cell cycle
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2, , , ,,,Active,0.37196359180909944,2.6386119094072016,10,1,0.04698980683529999,0.281551195,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Less than 50% efficacy""]",1,1,-0.0393766701528977,20,gpcr
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,70.1949709353784,3.5097485467689196,50.21756175489319,1.70085562231354,1.53481347591287,49.3752183,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.31148867773763,0.576819638758631,0.771119882483584,20,malformation
CCTE_Shafer_MEA_acute_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,88.4965217911214,1.2754691857221299,16.172602689823844,1.208779917424661,23.12783478209955,69.96270404455112,percent_activity,1.60205999132796,69.38350434629865,"[""Borderline active"",""Only one conc above baseline, active""]",1.7923262433123255,1.7923262433123255,0.21428467874284463,20,neuroactivity
CEETOX_H295R_11DCORT_dn,"Data from the assay component CEETOX_H295R_11DCORT was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,1.01577299574346,1.7066144310739118,46.81267458095705,1.6703634546837,0.0991996177977032,1.01343545553379,log2_fold_induction,2,0.595197706786219,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.68921567486675,1.62253855705783,1.55108293206539,100,steroid hormone
CEETOX_H295R_ANDR_dn,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",, , , ,,,Active,5.39451909943056,7.156478069755929,29.945277158097873,1.47632833704539,0.125632539890173,4.48668886950879,log2_fold_induction,2,0.753795239341038,,0.837770476933066,0.566807358113909,0.704360654418726,100,steroid hormone
CEETOX_H295R_CORTIC_up,"Data from the assay component CEETOX_H295R_CORTIC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTIC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,2.74019821004181,2.3312181816192323,3.7100238429594254,0.569376700675002,0.195906031136227,2.17202002516428,log2_fold_induction,1,1.17543618681736,,0.484321471496958,0.183446019912251,-0.0838531700748185,100,steroid hormone
CEETOX_H295R_CORTISOL_dn,"Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,2.56241003069715,2.5253138550017606,35.264926117992474,1.54734297831016,0.169114954802015,2.56178222994565,log2_fold_induction,2,1.01468972881209,,1.52442307558495,1.47140268438151,1.42806266029615,100,steroid hormone
CEETOX_H295R_DOC_up,"Data from the assay component CEETOX_H295R_DOC was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_DOC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,2.5734352023736,2.949401637926523,15.665170262385598,1.19493511952495,0.145421315817738,2.46110978619452,log2_fold_induction,2,0.872527894906428,,0.998690116556825,0.727787502125573,0.548972832035641,100,steroid hormone
CEETOX_H295R_OHPREG_dn,"Data from the assay component CEETOX_H295R_OHPREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,0.954594958385833,1.2373782887710099,12.422011094111067,1.09419191277856,0.12857762349216,0.946785562143121,log2_fold_induction,1.47712125471966,0.77146574095296,,1.22930667797522,1.0576915834593,0.887754648214904,100,steroid hormone
CEETOX_H295R_OHPROG_dn,"Data from the assay component CEETOX_H295R_OHPROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,1.64504865473912,1.818391202314446,34.61665642916265,1.53928511771355,0.150778762810161,1.64471921831036,log2_fold_induction,2,0.904672576860966,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55016500159216,1.4866508172478,1.42000477237284,100,steroid hormone
CEETOX_H295R_PROG_up,"Data from the assay component CEETOX_H295R_PROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,2.24320702839326,2.4522653485880683,13.755395580914971,1.13847308444858,0.152458149882028,2.20449653967109,log2_fold_induction,2,0.914748899292168,,1.0412344039407,0.783491274223212,0.565862240893578,100,steroid hormone
CEETOX_H295R_TESTO_dn,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",, , , ,,,Active,5.52879637649643,5.541055575463052,29.76336100537288,1.47368197202398,0.166297928291831,4.54959170503964,log2_fold_induction,2,0.997787569750986,,0.918163493354806,0.625343527422852,0.667026188513146,100,steroid hormone
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2, , , ,"[27,27]",,Active,0.960173196149901,1.7107679436530634,3.019620872446031,0.47995241867216,0.187084246719363,1.43850590188296,log2_fold_induction,1,0.561252740158089,,0.498486928747493,0.498486928747493,0.360668957057245,20,transporter
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2, , , ,,,Active,1.11263052981786,2.932643072345111,0.07354140361860935,-1.13346808539999,0.126465046759354,1.13752213925655,log2_fold_induction,0,0.379395140278062,"[""Noisy data"",""Noisy data""]",-1.16923704255859,-1.16923704255859,-1.25274840030641,20,transporter
LTEA_HepaRG_ACLY_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001087.2, , , ,,,Active,0.777837068843964,2.2217774117804767,17.951010068970074,1.25408889052093,0.116698919330631,0.419816097845855,log2_fold_induction,1,0.350096757991893,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.06705652880979,1.06705652880979,-0.797525535948052,20,lyase
LTEA_HepaRG_ALPP_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001623.3, , , ,,,Active,1.04837073296812,1.0447841276829084,34.397208981302214,1.53652320497867,0.33447762243899,1.04815410357476,log2_fold_induction,2,1.00343286731697,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.70515634370266,1.70515634370266,1.41722615787699,20,phosphatase
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,2.64257335228456,2.9342993578930865,49.55784350606869,1.69511239992777,0.300193564683644,2.04083340532527,log2_fold_induction,2,0.900580694050932,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.47694112230467,1.47694112230467,0.968511715859585,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,2.62951040472036,3.488080100121031,32.08269298874763,1.50627081538102,0.251285361310856,2.62920760348042,log2_fold_induction,2,0.753856083932568,"[""Noisy data"",""Noisy data""]",1.45678771780868,1.45678771780868,1.38699037428791,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,2.25766008235369,4.71399151363933,17.648728454238505,1.24671342104393,0.159642493756543,1.52222489008571,log2_fold_induction,1,0.478927481269629,"[""Hit-call potentially confounded by overfitting"",""Noisy data"",""Noisy data"",""Hit-call potentially confounded by overfitting""]",0.507986482591774,0.507986482591774,0.00965823807660726,20,cyp
LTEA_HepaRG_CYP3A5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000768.1, , , ,,,Active,2.45314167265035,3.2086929591267843,4.124018713440422,0.615320627301458,0.254843296413747,1.37020959303429,log2_fold_induction,1,0.764529889241241,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",0.287787838207944,0.287787838207944,-0.292885151484857,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,1.97871990955785,3.095540050455765,35.72653444107733,1.55299089064654,0.213072127136213,1.54832153095413,log2_fold_induction,2,0.639216381408639,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.24875021811292,1.24875021811292,0.649402256096184,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,1.64370585437544,2.0349413660393973,9.86462097833037,0.9940804033052,0.269247045935707,1.51707106611836,log2_fold_induction,2,0.807741137807121,,0.978747878178788,0.978747878178788,0.0131742224592353,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,2.24417752935206,4.178155774955319,49.729129216975565,1.69661085457561,0.179040518530855,1.35917056544459,log2_fold_induction,1,0.537121555592565,,0.48061597667122,0.48061597667122,-0.614044968199185,20,cyp
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,0.417963059481207,1.1372040146260858,0.9460371045334911,-0.0240918297946817,0.122511895873739,0.74754293760519,log2_fold_induction,1,0.367535687621217,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",0.533577094902448,0.533577094902448,-0.640983697554819,20,lyase
LTEA_HepaRG_HGF_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000592.3, , , ,,,Active,0.794487584224148,1.1190693348127592,2.1694697492096893,0.336353598764424,0.236651283797079,1.0341804091291,log2_fold_induction,1,0.709953851391237,"[""Borderline active"",""Borderline active""]",0.739741272997703,0.739741272997703,-0.0801467651280026,20,growth factor
LTEA_HepaRG_IL6R_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000556.1, , , ,,,Active,0.988552250379966,2.5246291900067033,4.296222177037734,0.633086732599897,0.130521114981027,0.564876006027351,log2_fold_induction,1,0.391563344943081,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",0.47943936430349,0.47943936430349,-0.167379875989832,20,cytokine receptor
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1, , , ,,,Active,1.00545347934016,1.47959244099781,2.5583786154409824,0.407964816307259,0.226515863756396,1.49580007535237,log2_fold_induction,1,0.679547591269188,,0.447856070161238,0.447856070161238,0.288683620431251,20,dna binding
LTEA_HepaRG_TGFB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,P01137.2, , , ,,,Active,0.434515922738006,1.2690535968139298,81.76736495864819,1.91258000237045,0.114131224462307,0.36127378126429,log2_fold_induction,2,0.342393673386921,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.984607832838,1.984607832838,1.79203160664505,20,growth factor
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1, , , ,,,Active,1.03799762549723,1.068093888041517,1.0471413430989889,0.020005306688316,0.323940818661091,1.58934447728997,log2_fold_induction,1,0.971822455983273,"[""Borderline active"",""Borderline active""]",0.165869734294942,0.165869734294942,-0.099277414611556,20,growth factor
LTEA_HepaRG_TIMP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003245.1, , , ,,,Active,0.753297839166003,2.038444231672322,96.23103889429984,1.98331517439046,0.123181824560391,0.4340159047518,log2_fold_induction,2,0.369545473681173,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.98126345741198,1.98126345741198,1.86381238154775,20,protease inhibitor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,0.845552163347373,1.2766203864163255,42.72592470070274,1.63069147076239,0.220778803248623,0.84460696798221,log2_fold_induction,1,0.662336409745869,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.70049941890395,1.70049941890395,1.51133683205959,20,transferase
NVS_ADME_hCYP1A1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000490.1, , , ,"[57,57]",,Active,45.5944153053885,2.279720765269425,3.552099760184529,0.550485154372683,1.8911470059282,39.7222862031522,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.456085903606442,-0.196277447768511,-0.290476386160782,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1, , , ,,,Active,87.8229721997332,4.39114860998666,7.6651465343438145,0.884520461662492,2.60299124232151,73.1858101675552,percent_activity,1.30102999566398,20,,0.474953548528422,0.104093687962093,0.147594845099623,20,cyp
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2, , , ,,,Active,61.9132189359625,3.095660946798125,8.372030960904448,0.922830825749436,2.17335298616219,51.5943491422805,percent_activity,1.30102999566398,20,,0.721569484105544,0.340817959330211,0.325135326279098,20,cyp
NVS_ENZ_rMAOAC,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",P21396.1, , , ,,,Active,51.1175138909126,2.55587569454563,19.83516847749197,1.29743589366998,3.12466620760733,51.0859582659991,percent_activity,1.69897000433602,20,,1.2734390133314,1.21635281522175,1.17815548910022,20,oxidoreductase
NVS_ENZ_rMAOAP,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",P21396.1, , , ,,,Active,46.0599013049532,1.8012551228044902,31.064582031793954,1.49226551463651,4.26183394029155,38.383252041101,percent_activity,1.69897000433602,25.5710036417493,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.52079111602548,1.36912906798573,1.20939558658978,20,oxidoreductase
NVS_NR_cAR,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001009012.1, , , ,,,Active,34.3403565098439,1.717017825492195,23.993036867328456,1.38008522134221,2.67547881471795,28.6169637705366,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.46894153069428,1.06292680458764,0.793178321573546,20,nuclear receptor
NVS_OR_gSIGMA_NonSelective,"Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",NP_001166463.1, , , ,,,Active,40.9790138519586,1.9295846049038996,19.798787140778426,1.29663858651402,3.53953676072849,40.9538976033124,percent_activity,1.69897000433602,21.2372205643709,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3006025551735,1.23960739583612,1.17735574544097,20,misc protein
NVS_TR_gDAT,"Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_034150.1, , , ,,,Active,88.136970019435,3.9650302682582383,16.660088810901588,1.22167731219572,3.70476238752447,73.4474750225703,percent_activity,1.69897000433602,22.2285743251468,,0.859033987975935,0.575768721786715,0.488566466114935,20,transporter
NVS_TR_hNET,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_001034.1, , , ,,,Active,63.4768533362736,2.443704561437338,16.598168209787573,1.2200601615173,4.32927765614309,52.8973777921657,percent_activity,1.69897000433602,25.9756659368585,,1.10041067984879,0.777664358809014,0.504134539459058,20,transporter
NVS_TR_rNET,"Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",CAA73665.1, , , ,,,Active,85.082057569369,4.25410287846845,13.158326975917612,1.11920067413233,3.25713321860448,70.9017146723423,percent_activity,1.69897000433602,20,,0.62366579248249,0.261544753143988,0.196422404493313,20,transporter
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,86.7876545266975,2.0851330189399,55.31000479624742,1.74280369612933,8.32442378863878,69.7385300332025,percent_activity,2,41.6221189431939,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72432928930844,1.537866360963,1.24597211600897,20,nuclear receptor
TOX21_AhR_LUC_Agonist,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1, , , ,"[57,131,21,41,150,310,131,21,57,310,41,150]",[165],Active,114.168243466111,5.7084121733055495,19.96670062235484,1.30030630623837,1.20983399992497,100.6129381698,percent_activity,1.95424250943932,20,,0.690715526961757,-0.0438225733090809,0.435810092554614,20,dna binding
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,74.1182442775105,2.1920741671320814,82.30435479856625,1.91542281473781,5.63532060098133,45.6843531652,percent_activity,1.95424250943932,33.811923605888,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.8466889762544,1.43849586623115,1.05584307764234,20,channel 2
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,80.4321614359451,4.021608071797255,134.55319839812128,2.12889402562371,2.50978290890691,35.8304984269,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.62673470204737,1.09790030016625,1.13109368208356,20,dna binding
TOX21_CAR_Agonist,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1, , , ,,,Active,70.3604325254706,3.51802162627353,52.72499883016467,1.72201657877562,0.83822208889671,58.0729749231,percent_activity,1.95424250943932,20,,1.28963231265077,0.179202396901473,0.693242811657448,20,nuclear receptor
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,56.5926663095277,2.357967032970489,53.68322946941814,1.72983863418329,4.0001030208237,56.6513805325,percent_activity,1.95424250943932,24.0006181249422,,1.71322747524113,1.65858011027081,1.61055828035909,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,93.0923834087317,4.315948070165138,88.25042422043695,1.94571680172164,3.59489896137582,50.8208883614,percent_activity,1.95424250943932,21.5693937682549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88064083553608,1.83538774339238,1.8264364860076,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,67.3095431162779,2.568868937102229,52.23864419592693,1.71799189671517,4.36700254498032,67.4342459149,percent_activity,1.95424250943932,26.2020152698819,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69354356176263,1.64089651882942,1.59871157366498,20,cell cycle
TOX21_ERa_LUC_VM7_Agonist,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,200,29,165,53,52,167,112,30,67,29,165,53,52,30,67,112,167]",[1181],Active,24.0372879462138,1.2018643973106902,5.336527521458711,0.72725875350498,2.77515618820713,21.7344856166,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.37749385667717,0.469184184449393,-0.165597802501481,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,34.0634635989011,1.657607318554027,56.84439217122104,1.75468762699699,3.42496311979521,23.0994623745,percent_activity,1.95424250943932,20.5497787187713,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.8928461036344,1.47797256550224,1.03044296168016,20,cell cycle
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1, , , ,,,Active,61.1144029198734,3.05572014599367,68.02602856666446,1.83267511711772,1.1538473582706,50.1425578093,percent_activity,2.30102999566398,20,,1.59964235001952,0.923108921816309,1.12214681942509,20,dna binding
TOX21_HDAC_Inhibition,"Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",, , , ,,,Active,21.5146122541429,1.075730612707145,39.983437801373576,1.60188013230284,1.55464412909631,20.9641941184,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.74197120631144,1.53214698065834,1.48259981195858,20,hydrolase
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,37.126931132093,1.85634655660465,68.5217475929739,1.83582843077197,2.51198214229767,22.3477314342,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.88690795634378,1.38531407085338,1.11211747075135,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,92.839873684776,4.6419936842388,45.11253355739498,1.65429721812184,1.80636679455099,71.0541452875,percent_activity,1.95424250943932,20,,0.854300414692171,-0.0668477115568222,0.294351265440453,20,nuclear receptor
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,84.2299607076208,3.127902462110654,36.092031228448405,1.5574113244669,4.48809608184861,84.0765174781,percent_activity,1.90308998699194,26.9285764910917,,1.51641735974947,1.46733141960047,1.43813101054468,20,cell cycle
TOX21_TSHR_HTRF_Antagonist_ch2,"Data from the assay component TOX21_TSHR_HTFR_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTFR_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,68.8095951247417,3.4404797562370852,45.15419523374659,1.65469810641531,3.2181984949422,53.1005683251,percent_activity,1.95424250943932,20,,1.40134883260386,1.13995270056665,1.03077006958711,20,channel 2
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,62.3694893102195,1.6422707989360399,57.29176767556715,1.75809222214316,12.6591971211703,41.6165281718045,percent_activity,2,37.9775913635109,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",2.03319080870143,2.03319080870143,0.392852587731984,20.000200271606445,nuclear receptor